Anticipation

Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 4, 2022
Cell, Private Securities Litigation Reform Act, Annual report, Partnership, MMA, Gout, Degenerative disease, IND, Achievement, Immune tolerance, Immunoglobulin A, Intellectual property, Investor, DMD, Anticipation, Poster, II, Development, Safety, Autoimmunity, Disease, Pandemic, LGMD, Intention, GLOBE, Income, Preclinical development, PBC, Antibody, Primary, AAV, Completeness, Glycogen storage disease, Patient, Review, U.S. Securities and Exchange Commission, Primary biliary cholangitis, Autoimmune disease, Administration, Telephone, Clinical trial, Mouse, Nanoparticle, Company, Duchenne muscular dystrophy, Â, Society, Biotechnology, CSO, Research, Muscular dystrophy, NASDAQ, Immunoglobulin G, Pharmaceutical industry, Dentistry, Vaccine, Health insurance, Life insurance, Gene, Swedish Orphan Biovitrum, IgA nephropathy, Selecta

Building on this momentum, we enter the second half of 2022 with a focused portfolio of proprietary programs and an expected financial runway into mid-2024.

Key Points: 
  • Building on this momentum, we enter the second half of 2022 with a focused portfolio of proprietary programs and an expected financial runway into mid-2024.
  • Selecta is working with its partner, Cyrus Biotechnology, to develop a next generation IL-2 molecule to combine with ImmTOR and anticipates selecting an IL-2 candidate by year end 2022.
  • Selecta completed enrollment for DISSOLVE II in June 2022, with 153 study participants, triggering a $10 million milestone payment obligation from Sobi which has been received in Q3 2022.
  • Selecta management will host a conference call at 8:30 AM ET today to provide a corporate update and review the companys second quarter 2022 financial results.

KBRA Assigns Preliminary Ratings to VCP RRL ABS II, LLC

Retrieved on: 
Tuesday, June 14, 2022
Banking, Professional Services, Insurance, Finance, European Securities and Markets Authority, Vista Equity Partners, Anticipation, LLC, KBRA, ESG, Ontario Securities Commission, Pressure, RRLS ICT Academy, VCP, Software, Class, Jetivia SA v Bilta (UK) Limited (in liquidation), RRL, National Association of Insurance Commissioners, CRA, U.S. Securities and Exchange Commission, National Association, UK, Note, Prospectus, Kansas Insurance Commissioner, CCC, Credit, VEP, Bank, Security (finance)

KBRA assigns preliminary ratings to three classes of notes issued by VCP RRL ABS II, LLC.

Key Points: 
  • KBRA assigns preliminary ratings to three classes of notes issued by VCP RRL ABS II, LLC.
  • (VCP RRL II), a securitization backed by a portfolio of recurring revenue and middle market corporate loans.
  • VCP RRL ABS II, LLC is a $370.0 million securitization managed by Vista Credit Partners, LLC (Vista or the Collateral Manager), an affiliate of Vista Equity Partners Management, LLC.
  • Kroll Bond Rating Agency, LLC (KBRA) is a full-service credit rating agency registered with the U.S. Securities and Exchange Commission as an NRSRO.

Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 5, 2022
Completeness, MMA, Immunoglobulin G, Immunoglobulin A, Telephone, NASDAQ, GLOBE, Development, Company, Private Securities Litigation Reform Act, AAV, Primary biliary cholangitis, Methylmalonic acidemia, Research, Immune tolerance, Â, Patient, Autoimmune disease, Review, Anticipation, Clinical trial, FDA, Administration, Degenerative disease, PBC, Glycogen storage disease, Pandemic, Intention, Disease, Intellectual property, U.S. Securities and Exchange Commission, Investor, Gout, Animal, Vaccine, Pharmaceutical industry, Security (finance), IND, Selecta, IgA nephropathy

Selecta is working with its partner, Cyrus Biotechnology, to develop a next generation IL-2 molecule to combine with ImmTOR.

Key Points: 
  • Selecta is working with its partner, Cyrus Biotechnology, to develop a next generation IL-2 molecule to combine with ImmTOR.
  • Selecta continues work toward identifying suitable target indications and accelerating the development of ImmTOR-IL to the clinic.
  • Selecta expects initiation of the Phase 1 clinical trial of SEL-302 in the second half of 2022.
  • Selecta management will host a conference call at 8:30 AM ET today to provide a corporate update and review the companys first quarter 2022 financial results.

Service Providers Can Now Improve Efficiency of Broadband Operations Up to 98 Percent Thanks To Latest Enhancements to Calix Cloud

Retrieved on: 
Tuesday, February 15, 2022
Data Management, Consumer Electronics, Technology, Security, Other Technology, Telecommunications, Software, Networks, Internet, Mobile, Wireless, Hardware, Cloud, Form 10-Q, NYSE, Mark (given name), SEC, Forward-looking statement, Efficiency, Annual report, EXA, Calix Inc., History of science and technology, Element, Anticipation, Lightning, Partnership, Acquisition, Automation, City centre, Growth, Intelligence, Industry, Mobile phone, Risk management, Calix, Operation

With the launch of new capabilities in Calix Operations Cloud (Operations Cloud), built on the Calix Cloud platform, even the smallest broadband service providers (BSPs) can achieve amazing efficiency across the entire subscriber-facing network.

Key Points: 
  • With the launch of new capabilities in Calix Operations Cloud (Operations Cloud), built on the Calix Cloud platform, even the smallest broadband service providers (BSPs) can achieve amazing efficiency across the entire subscriber-facing network.
  • The latest enhancements to Operations Cloud enable end-to-end service provisioning for the first time.
  • The latest enhancements in Operations Cloud further help BSPs transform their business models and monetize the networks theyve invested millions to build.
  • Calix, Inc. (NYSE: CALX) Calix cloud and software platforms enable service providers of all types and sizes to innovate and transform.

CLARIOS ANNOUNCES SMART TECHNOLOGY TO PROVIDE REAL-TIME VEHICLE PERFORMANCE OPTIMIZATION, MONITORING OF CRITICAL SAFETY FUNCTIONALITY FOR EVs, AUTONOMOUS VEHICLES

Retrieved on: 
Monday, January 10, 2022
Safety, AGM, GameChanger, Smart, Anticipation, Product management, Industry, Crash, Brookfield Business Partners, EVS, Time, Electronics, EV, Original equipment manufacturer, Maintenance, Mobile phone, Electric battery

Clarios Smart AGM (absorbent glass mat) will monitor its performance in real-time, deliver continuous low-voltage power to optimize performance of the low-voltage power supply, anticipate the need for battery maintenance and provide safety critical operations.

Key Points: 
  • Clarios Smart AGM (absorbent glass mat) will monitor its performance in real-time, deliver continuous low-voltage power to optimize performance of the low-voltage power supply, anticipate the need for battery maintenance and provide safety critical operations.
  • EVs require an advanced low-voltage battery as a key component of a multi-battery system to help provide continuous low-voltage power and provide crucial safety functionality in critical moments of emergency.
  • As more autonomous features are added to vehicles, there will be an even greater reliance on the low-voltage battery.
  • "The Clarios Smart AGM will be a gamechanger for the industry, providing a reliable safety critical battery with real-time communications," said Mark Wallace, Clarios CEO.

Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, December 2, 2021
Patient, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Therapeutic index, Pharming, Exercise, Research and development, Cancer, GPS, Tumor microenvironment, IPO, IND, SEC, Clinical trial, Solution, COVID-19, Goal, Cytokine, U.S. Securities and Exchange Commission, Prospectus, Annual general meeting, Pembrolizumab, Society, Research, R, GLOBE, Biotechnology, Patent, FDA, General Administration of Sport of China, G&A, Immune system, Therapy, Administration, Society for Immunotherapy of Cancer, Toxicity, Food, Immunotherapy, Anticipation, Pharmaceutical industry, Medical imaging, Lithium

WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today reported recent pipeline and business progress and third quarter 2021 financial results.

Key Points: 
  • In November 2021, at the Society for Immunotherapy in Cancers 36th Annual Meeting, Xilio reported data from preclinical studies for XTX301, a tumor-selective interleukin-12 (IL-12).
  • Research & Development (R&D) Expenses: R&D expenses were $10.5 million for the third quarter of 2021, compared to $11.5 million for the third quarter of 2020.
  • General & Administrative (G&A) Expenses: G&A expenses were $5.5 million for the third quarter of 2021, compared to $3.2 million for the third quarter of 2020.
  • Net Loss: Net loss was $16.3 million for the third quarter of 2021, compared to $14.8 million for the third quarter of 2020.

Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 3, 2021
Safety, Promotion, PDUFA, Partnership, Adoption, UTC, Trial of the century, COVID-19, IPR, District court, Acquisition, GLOBE, ANDA, Lung, Judgement, Hearing, Private Securities Litigation Reform Act, Endpoint security, Achievement, Pulmonary hypertension, Income, NDA, Temperature, INSPIRE, Peru–United States Trade Promotion Agreement, Physician, Industry, USPTO, Goal, PAH, 1836 U.S. Patent Office fire, Abbreviated New Drug Application, SEC, PTAB, LLC, Environment, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Pharmacology, Patient, NASDAQ, FDA, Review, Hypertensive emergency, District, Patent, Research, Anticipation, Coronavirus, Pharmaceutical industry, Animal, Generic drug

MORRISVILLE, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the quarter and nine-months ended September 30, 2021.

Key Points: 
  • These pre-approval inspections were completed in August 2021 and October 2021, respectively.
  • More recently in October 2021, the PTAB ruled in Liquidias favor in the IPR proceeding against U.S. Patent No.
  • Revenue recognized during 2021 related primarily to the promotion agreement with Sandoz Inc., after the acquisition of Liquidia PAH in November 2020.
  • The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC.

Stericycle's Defensive Driving Program Wins Brandon Hall Group Gold Award

Retrieved on: 
Thursday, October 28, 2021
Safety, Benchmarking, Research, Technology, Leadership development, Equity, Organization, SWAT, Transport, Insurance, Waste, Government, Science and technology in Asia, Conference, Swanson Health Products, OSHA, Sexual abuse, Silver, HIPAA, COVID-19, Environment, Growth, HCM, Gold, American Business Women's Association, Solution, Health, Nasdaq, Anticipation, Development, Human resource management, Training, Culture, Acqui-hiring, Medicine, Risk management, Management

Stericycle, together with its training curriculum partner, Judge Learning Solutions, was honored with a gold awardfor its SWAT defensive driving certification program.

Key Points: 
  • Stericycle, together with its training curriculum partner, Judge Learning Solutions, was honored with a gold awardfor its SWAT defensive driving certification program.
  • "We are honored to receive this prestigious award from the Brandon Hall Group and to be recognized for the strides we are making to protect what matters."
  • Brandon Hall Group operates the largest and longest running awards program in Human Capital Management.
  • Brandon Hall Group has also launched professional certifications for business and human capital management professionals to upskill themselves and gain credentials for career advancement.

Samsonite Spreads Message of Hope for Future Travel with New 'Travel is a Gift' Video

Retrieved on: 
Thursday, December 3, 2020
Creative works, Software, Musicians, Emotions, Anticipation, Instagram, It, Nostalgia, Westlife

The video can be seen on Instagram , Facebook and YouTube as well as on Samsonite.com through December and into the new year.

Key Points: 
  • The video can be seen on Instagram , Facebook and YouTube as well as on Samsonite.com through December and into the new year.
  • "We want to provide both nostalgia for past travel but even more, a real sense of hope to people who love to travel that better times and new adventures are ahead.
  • We know that the trend of 'revenge travel' is coming in 2021.
  • That people have so much pent-up anticipation for amazing travel experiences and seeing loved ones once they are safe to do so and Samsonite will be here when they're ready."

Bionano Data Provides Understanding of Repeat Expansion Disorders Causing Muscular Dystrophy and ALS

Retrieved on: 
Thursday, September 17, 2020
Neurological disorders, RTT, Organ systems, Branches of biology, C9orf72, Myotonic dystrophy, Amyotrophic lateral sclerosis, Trinucleotide repeat disorder, Dystrophy, Anticipation

Saphyr identified repeat expansions in patients with ALS and DM that were so large that only Saphyr is capable of sizing them correctly.

Key Points: 
  • Saphyr identified repeat expansions in patients with ALS and DM that were so large that only Saphyr is capable of sizing them correctly.
  • These symptoms, caused by an abnormal processing of a number of brain-expressed genes, correlate with the length of a repeat expansion.
  • Separately, in an online presentation by Dr. Mark Ebbert from the Mayo Clinic, Saphyr data was used to measure the repeat expansion in the C9ORF72 gene that causes ALS.
  • We are focused on developing better tools for the detection and molecular diagnosis of a range of repeat expansion disorders, including those causing Myotonic Dystrophy and ALS, where current methods fail to accurately size the repeats.